To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05468489. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Study identification
- NCT ID
- NCT05468489
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Serplulimab + chemotherapy (carboplatin-etoposide) Drug
- Atezolizumab + chemotherapy (carboplatin-etoposide) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2022 (Actual)
- Primary completion
- Feb 28, 2026 (Actual)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Nov 12, 2026
2022 – 2027
United States locations
- U.S. sites
- 65
- U.S. states
- 30
- U.S. cities
- 63
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology | Birmingham | Alabama | 35223 | — |
| City of Hope - Phoenix | Goodyear | Arizona | 85338 | — |
| Arizona Clinical Research Center (ACRC) | Tucson | Arizona | 85715 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Compassionate Care Research Group | Fountain Valley | California | 92708 | — |
| Providence Medical Foundation | Fullerton | California | 92835 | — |
| Los Angeles Cancer Network | Glendale | California | 91204 | — |
| OPN - Oncology Physician Network | Los Alamitos | California | 90720 | — |
| Kaiser Permanente Research (Southern California) | Los Angeles | California | 90034 | — |
| UC Davis | Sacramento | California | 95817 | — |
| UCHealth Memorial Hospital North | Colorado Springs | Colorado | 80920 | — |
| MD Anderson- North Colorado Medical Center | Greeley | Colorado | 80631 | — |
| Advanced Cancer Treatment Centers | Brooksville | Florida | 34613 | — |
| Cancer Specialists North Florida | Jacksonville | Florida | 32256 | — |
| Mount Sinai Comprehensive Cancer Center | Miami | Florida | 33140 | — |
| Florida Cancer Affiliates- (Ocala Oncology - Main) | Ocala | Florida | 34473 | — |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | — |
| BRCR Global | Plantation | Florida | 33322 | — |
| Napa Research | Pompano Beach | Florida | 33064 | — |
| Advanced Research | Tamarac | Florida | 33321 | — |
| Straub Benioff Medical Center | Honolulu | Hawaii | 96814 | — |
| City of Hope- Chicago | Chicago | Illinois | 60099 | — |
| Cancer Center of Decatur | Decatur | Illinois | 62526 | — |
| Accellacare of Duly | Tinley Park | Illinois | 60487 | — |
| Northwest Cancer Centers | Dyer | Indiana | 46311 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Baptist Health Lexington | Lexington | Kentucky | 40503 | — |
| Pikeville Hospital | Pikeville | Kentucky | 41501 | — |
| CHRISTUS St. Frances Cabrini Cancer Center | Alexandria | Louisiana | 71301 | — |
| Pontchartrain Cancer Center | Hammond | Louisiana | 70433 | — |
| Henry Ford Health Providence Southfield Hospital | Southfield | Michigan | 48075 | — |
| Health Partners Cancer Center at Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| Hattiesburg Clinic Hematology/Oncology | Hattiesburg | Mississippi | 39401 | — |
| MidAmerica Division Inc., c/o Research Medical Center | Kansas City | Missouri | 64132 | — |
| Lake Regional | Osage Beach | Missouri | 65065 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68106 | — |
| Renown Health | Reno | Nevada | 89502 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Regional Cancer Care Associates LLC RCCA | Freehold | New Jersey | 03756 | — |
| Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | — |
| Elmhurst (BRANY site) | Elmhurst | New York | 11373 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| Stony Brook Cancer Center | Stony Brook | New York | 11794 | — |
| Great Lakes Cancer Care (Kaleida Health) | Williamsville | New York | 14221 | — |
| Summa Health | Akron | Ohio | 44304 | — |
| Cleveland Clinic Mercy Hospital | Canton | Ohio | 44708 | — |
| Aultman Cancer Center | Canton | Ohio | 44710 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Tricounty Hematology and Oncology Associates | Massillon | Ohio | 44646 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| CharterCARE (Roger Williams) | Providence | Rhode Island | 02908 | — |
| CHRISTUS Institute for Innovation & Advanced Clinical Care | Corpus Christi | Texas | 78404 | — |
| DHR Research | Edinburg | Texas | 78539 | — |
| Millennium Research and Clinical Development | Houston | Texas | 77090 | — |
| Lumi Research | Kingwood | Texas | 77339 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410 | — |
| The University of Texas Health Science Center at Tyler/HOPE Cancer Center | Tyler | Texas | 75701 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| American Oncology Network Vista Oncology Division | Olympia | Washington | 98502 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| West Virginia University Cancer Institute | Morgantown | West Virginia | 26505 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
| Froedtert Hospital- Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05468489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2026 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.